RLMD – relmada therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: Ikarian Capital, LLC
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Shenouda Maged
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Ence Chuck
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: TRAVERSA SERGIO
Form 4 RELMADA THERAPEUTICS, For: Nov 05 Filed by: Kelly Paul Edward
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.